✦ LIBER ✦

Disposition and Metabolism of the Cathepsin K Inhibitor Odanacatib in Humans

✍ Scribed by Kassahun, K.; McIntosh, I.; Koeplinger, K.; Sun, L.; Talaty, J. E.; Miller, D. L.; Dixon, R.; Zajic, S.; Stoch, S. A.

Book ID: 121861032
Publisher: American Society for Pharmacology and Experimental Therapeutics
Year: 2014
Tongue: English
Weight: 951 KB
Volume: 42
Category: Article
ISSN: 0090-9556
DOI: 10.1124/dmd.113.056580

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Metabolism and Disposition of the Or

The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans

✍ Blech, S.; Ebner, T.; Ludwig-Schwellinger, E.; Stangier, J.; Roth, W. 📂 Article 📅 2007 🏛 American Society for Pharmacology and Experimental 🌐 English ⚖ 366 KB

Azepanone-Based Inhibitors of Human and

Azepanone-Based Inhibitors of Human and Rat Cathepsin K

✍ Marquis, Robert W.; Ru, Yu; LoCastro, Steven M.; Zeng, Jin; Yamashita, Dennis S. 📂 Article 📅 2001 🏛 American Chemical Society 🌐 English ⚖ 321 KB

Treatment With the Cathepsin K Inhibitor

Treatment With the Cathepsin K Inhibitor Odanacatib in Postmenopausal Women With Low BMD: 5 Year Results of a Phase 2 Trial

✍ Watts, Nelson; Binkley, Neil; Bone, Henry; Gilchrist, Nigel; Langdahl, Bente; Re 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 222 KB

Odanacatib, a cathepsin-K inhibitor for

Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density

✍ Henry G Bone; Michael R McClung; Christian Roux; Robert R Recker; John A Eisman; 📂 Article 📅 2009 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 276 KB

Treatment with the cathepsin K inhibitor

Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial

✍ B. Langdahl⁎; N. Binkley; H. Bone; N. Gilchrist; H. Resch; J. Rodriguez Portales 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Treatment with the cathepsin K inhibitor

Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial

✍ H. Resch; N. Binkley; H. Bone; J.A. Eisman; N. Gilchrist; B. Langdahl; J. Rodrig 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB